Funding Multi-indication Medicines: A Scoping Review of Health Technology Assessment and Reimbursement Frameworks Authors: Isaiah Luc, Mah Laka, Drew Carter, Tracy Merlin Published: 2025 ABSTRACT AbstractBackgroundMedicines with multiple indications pose efficiency problems for health technology assessment (HTA). Evaluating indications separately may result in years of duplicative evaluation work and ultimately delay patient access. The price of these medicines is also difficult to determine because the value may vary between the different indications.ObjectivesA scoping review was conducted to identify HTA and reimbursement frameworks for evaluating and pricing multi-indication medicines for reimbursement decisions and to explore whether there are elements in these frameworks that would have utility if implemented in jurisdictions with well-established HTA systems.MethodsPubMed, Embase and Scopus were systematically searched and a targeted search of HTA agency websites was conducted in September 2025. Documents were included in the review if they discussed HTA and reimbursement frameworks concerning multi-indication medicines in high-income countries.ResultsSixteen frameworks were identified, describing four main approaches: policy (3), pricing (6), HTA evaluation methods (4) and decision-making (3). Policy approaches included implementing conditional listing processes and streamlining the evaluation of multi-indication medicines. Pricing frameworks including indication-based pricing frameworks and volume-based agreements were reported most frequently.ConclusionsWhile pricing frameworks are commonly used in high-income countries, they do not help reduce duplication of effort in the evaluation and appraisal of these medicines. Policy change allowing for the streamlined incremental evaluation of each new indication may be helpful, although the methodological characteristics of a streamlined HTA have yet to be defined. Subscription-based approaches to purchasing medicines represent another option. Stakeholder engagement is needed to determine the merit and feasibility of different approaches.Supplementary InformationThe online version contains supplementary material available at 10.1007/s40258-025-01020-4. Key Points for Decision Makers Standard HTA processes and frameworks are not optimised to manage multi-indication medicines as there are efficiency issues that impact on timely patient access to new medicines.This scoping review found that conditional listing and subsequent assessment using real-world evidence was the only approach which was reported to accelerate patient access to multi-indication medicines.Payment models that can balance value and the budget impact of these medicines can also be adopted to reduce the expenditure of any one medicine to taxpayers. Introduction Over the last decade, there has been a significant increase in the development of medicines with multiple uses [1, 2]. There are three broad groups of multi-indication medicines, with uses across: diseases (e.g. rituximab for cancer and auto-immune disease), therapeutic areas (e.g. pembrolizumab for different types of cancer) and lines of therapy (e.g. trastuzumab for initial and later lines of therapy in a specific cancer) [3–6]. Medicines that can be used in multiple indications play a significant role in facilitating timely patient access to new therapies, since developing medicines for subsequent indications can eliminate 5–7 years from the traditional 15-year development timeline [7, 8]. However, even after completing clinical trials and registration, many new medicines are still unattainable for the average patient owing to their high up-front costs [9]. Australia, like many other countries with developed healthcare systems, uses formal health technology assessment (HTA) processes to help decide which medicines to reimburse [1, 10]. The Pharmaceutical Benefits Advisory Committee (PBAC) is responsible for recommending whether new medicines should be listed on the Pharmaceutical Benefits Scheme for government reimbursement [11]. PBAC recommendations are informed by HTAs, which evaluate a medicine’s safety, clinical effectiveness, cost-effectiveness, budgetary implications and other dimensions in comparison with one or more currently reimbursed treatment alternatives (the comparator(s)) [10, 12]. The aim of this scoping review is to identify international HTA and reimbursement frameworks that could feasibly address the problems posed by multi-indication medicines. As HTA ‘globalises the evidence and localises the decision’ [13], and therefore HTA approaches differ from country to country, the Australian HTA system was used as the exemplar target for applying potential solutions to the issues raised by multi-indication medicines. Efficiency of HTA Processes for Multi-indication Medicines Multi-indication medicines pose significant methodological and policy problems for HTA. Conventional evaluation frameworks assess the safety, efficacy and cost-effectiveness of a medicine against a single comparator for each indication, hence pharmaceutical companies need to lodge separate submissions for each indication targeted by the same medicine [10]. This is resource-intensive and costly for pharmaceutical companies, as each submission requires a dossier of the medicine’s clinical and economic evidence and attracts a substantial fee (more than 250,000 AUD in Australia, 161,199 USD), noting that previous analyses have shown—in the Australian context—that multiple submissions (for the same medicine–indication pair) are usually required before a positive funding recommendation is made [14–16]. In Australia, each medicine assessment involves 17 weeks of evaluation and appraisal activity by academic HTA groups and the PBAC sub-committees. For medicines with multiple indications, this could generate years of evaluation work and involve substantial duplication of effort (e.g. reviewing similar evidence on drug safety on multiple occasions). Increasing efficiency and reducing the assessment burden of multi-indication medicines is particularly important given that global demand for health technologies exceeds evaluation workforce capacity [17, 18]. Recently, the PBAC had to delay reimbursement decisions for a number of medicines owing to evaluation capacity limits [19]. The Value and Price of Multi-indication Medicines In line with value-based pricing, the prices of medicines in many jurisdictions are partly based on the additional clinical benefit that they bring over the existing appropriate alternative treatment [20–24]. As multi-indication medicines vary in the level of clinical benefit experienced by patients across different indications, it is appropriate for the price of a multi-indication medicine to vary depending on what it is being used for. This is known as indication-based pricing (IBP) [25]. Because medicines dispensed under the Pharmaceutical Benefits Scheme can be differentiated on the basis of indication, Australia has implemented IBP over recent decades [26]. While publicly listed prices for medicines suggest that a multi-indication medicine has a single price across all indications, research suggests that confidential (also known as actual or effective) prices are likely indication-specific and aligned more closely to the value of the medicine in the specific indication [3, 22]. When the public price of a medicine does not accurately reflect the value of the medicine in any one indication, this can create problems if the price is used for reference pricing between countries, or if the medicine is used as a comparator in an economic evaluation [25, 27]. Additionally, as submissions are lodged on a per-indication basis, the budget impact of a multi-indication medicine across all indications may never be formally assessed, and hence, larger patient populations and prescription volumes are not considered. This is contrary to what happens with price negotiations concerning single-indication medicines [3, 6, 22, 28]. In short, price negotiation for multi-indication medicines may be under-informed as the budget impact is only ever assessed on a per-indication basis. Study Aim While standard HTA processes can be applied to multi-indication medicines, they are resource-intensive and possibly duplicative and may delay patient access while failing to capture the true value and budget impact of these medicines. However, despite these issues, there are currently no reviews of international HTA practices for reimbursement that address medicines with multiple indications, making this review the first of its kind. The aim of this study is to identify frameworks and processes tailored to assessing and pricing multi-indication medicines for a funding decision. A further aim is to explore which elements from those frameworks and processes could be usefully implemented in well-established HTA systems, such as in Australia—where revision of HTA processes are also currently underway [18]. A scoping review was the methodology chosen, as the study aim is to provide a synthesis of evidence describing current approaches [29]. A scoping review also allows for canvassing heterogeneous literature, ranging from policy documents to cross-sectional studies (discussed further below) [30]. Methods Scoping Review Approach This scoping review followed methodology outlined by the JBI for scoping reviews and was reported using the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) extension for scoping reviews (PRISMA-ScR, presented in Appendix 1 in Supplementary Files) [30]. In line with the JBI methodology, a population–concept–context (PCC) matrix was developed (Table 1). This was achieved by adapting the matrix developed by Merlin et al. [31] to review international HTA processes, namely by limiting the PCC inclusion criteria to those processes and frameworks for HTA reimbursement decisions that address multi-indication medicines. Table 1Population–concept–context matrixPopulationConceptContextInternational stakeholders in HTA, including academics, decision-makers, evaluators, consumers, and industryInternational and national processes, pathways and frameworks for the HTA or reimbursement of multi-indication medicines for funding decisionsHTA in developed countries and jurisdictions with health systems similar to AustraliaHTA health technology assessment Population–concept–context matrix HTA health technology assessment The literature search was performed in two parts: a peer-reviewed-literature search of bibliographic databases, then a grey-literature search of HTA agency websites. The lead researcher (I.L.) performed all the literature screening, and a random sample of 20% of retrieved articles was independently screened by another member of the research team (M.L.). Conflicts were resolved through consensus. Peer-Reviewed Literature Search A search of the published literature was conducted on 26 September 2025 using PubMed, Embase and Scopus. The final search queries (provided in Appendix 1, Supplementary Files) were refined using the Peer Review of Electronic Search Strategies guidelines. Duplicates were removed using the Systematic Review Accelerator Deduplicator function, and titles and abstracts were screened for eligibility according to the previously described PCC inclusion criteria (Table 1) using Rayyan [32, 33]. The inter-rater consistency between reviewers at the initial screen was calculated using a kappa statistic. This was followed by review of the full text of the paper and a further eligibility assessment against the PCC criteria. Where there was uncertainty about inclusion in the review, the documents were checked by the full research team. Citation mining was performed on the included documents and followed the same screening and selection approach. Grey Literature Search (HTA Agency Websites) The International Network of Agencies for Health Technology Assessment (INAHTA) is a professional network of 53 HTA agencies that contribute to health system decision-making (including the funding of medicines) for 33 countries [34]. A targeted search of INAHTA member agency websites was conducted to identify policy or guidance documents that met the criteria for inclusion as per the PCC matrix. Member agencies on the Organisation for Economic Co-operation and Development (OECD) low- or middle-income country list were excluded as the focus of the review was on healthcare systems comparable to Australia [31]. The list of websites searched is provided in Appendix 1 in the Supplementary Files. When websites indicated that relevant information was located on other websites (such as government websites), a targeted search of those websites was performed. Websites and documents not in English were translated into English using Google Translate. Data Extraction and Synthesis Data from the included documents were extracted and charted according to the categories that emerged from the data. Data were inductively coded into key themes by the lead researcher (I.L.) then narratively synthesised and tabulated. These categories were created during data familiarisation, with the creation of the categories directed by the concepts and assumptions that underpinned the overt content of the data [35]. A pre-developed data extraction table was designed and piloted to capture the key components of the HTA process described in the documents, including how each process or framework manages the assessment of clinical and economic evidence and pricing across indications. Other variables that were extracted (where reported) included whether the HTA processes for multi-indication medicines are currently active, the HTA workload required of the sponsor or payer, and any observed advantages or disadvantages of the processes (full data extraction table provided in Appendix 1 in Supplementary Files). The lead researcher (I.L.) extracted data from the included documents, and another member of the research team (M.L.) extracted data from a random selection of 20% of the included documents as a reliability check. Discrepancies in data extraction were resolved through discussion and culminated in consensus. The protocol for this scoping review was prospectively registered with the Open Science Framework (https://osf.io/a25rz). Results Overview The peer-reviewed literature database search was constructed to be sensitive, given the lack of clearly defined indexing terms for multi-indication medicine frameworks. The search identified 15,383 articles. The screening and selection process is given in Fig. 1. After full-text screening, 26 articles were included in the scoping review. Common reasons for exclusion were that the article did not address an HTA or reimbursement process (n = 38), the process was not designed specifically for multi-indication medicines (n = 34) or the article was a conference abstract with insufficient data for extraction (n = 28). A kappa statistic of 99% concordance in screening was achieved between the two researchers. PRISMA diagram. HTA health technology assessment, INAHTA International Network of Agencies for Health Technology Assessment, LMIC low- and middle-income country, OECD Organisation for Economic Co-operation and Development, PRISMA Preferred Reporting Items for Systematic reviews and Meta-Analyses After searching for grey literature on the websites of 43 HTA agencies, nine relevant documents were retrieved from Australia, the UK, Belgium, Denmark, Canada, Italy, Japan and the Netherlands. HTA documents relating to multi-indication medicines were not identified from the other HTA agencies. A further nine documents were identified from citation mining. Four main categories of frameworks for multi-indication medicines were identified: policy frameworks, evaluation methods, decision-making frameworks and pricing frameworks. Of the documents identified, 11 discussed policy frameworks, 27 discussed pricing frameworks, 11 discussed HTA evaluation methods and 4 discussed decision-making frameworks (Table 2). Table 2.Sources addressing each process and frameworkHTA process categoryProcess/frameworksNumber of sourcesRefs.Policy frameworksHTA using RWE after provisional reimbursement7[1, 3, 37, 39–42]Re-assessment and price reduction when new indications have a substantial budget impact2[3, 28]Indication-specific RSAs4[36, 38, 42, 43]Pricing frameworksDifferent price for each indication16[3, 6, 43, 45, 47–49, 51, 52, 54, 56–60, 65]Different discounts applied to different indications11[3, 6, 25, 38, 45, 46, 48, 49, 51, 61, 65]Weighted average price18[3, 6, 25, 38, 42, 45–48, 51–53, 59, 60, 62–65]Volume-based discounts9[3, 6, 44–46, 48, 54, 55, 63]Uniform price for all indications6[6, 49, 57–59, 62]HTA evaluation methodsSingle ICER for each indication4[10, 50, 67, 91]Weighted ICER5[5, 50, 68, 69, 71]Pooled ICER4[64, 67, 69, 70]BIA for all indications1[66]Decision-making frameworksFull stratification4[36, 47, 50, 67]Partial stratification1[67]No stratification3[47, 50, 67]HTA health technology assessment, ICER incremental cost-effectiveness ratio, RSA risk-sharing arrangements, RWE real-world evidence Sources addressing each process and framework HTA health technology assessment, ICER incremental cost-effectiveness ratio, RSA risk-sharing arrangements, RWE real-world evidence Policy and Pricing Frameworks Table 3 provides an overview of the policy and pricing frameworks identified and their reported advantages and disadvantages. A detailed description of each framework is provided in Appendix 2 in Supplementary Files. Table 3.Policy and pricing frameworks for multi-indication medicinesFrameworkDescriptionReported advantagesReported disadvantagesPolicy frameworksHTA using RWE after provisional reimbursementThe payer and sponsor agree on (1) an initial price for a medicine for all indications (preliminary clinical and economic evidence can inform this) and (2) how RWE will be collected and analysed [3, 40, 41]. The medicine is then conditionally reimbursed for all (or selected) indications after a streamlined HTA for each indication and an agreement that the price of the medicine will be adjusted after a subsequent HTA using RWE [3, 40, 41]. These have been operationalised as MYMI agreements in several jurisdictions [1]Reduced reimbursement timeline from 395 to 30 days (Netherlands) and 220 to 120 days (Belgium) for immuno-oncology medicines [1]. No risk of arbitrage and launch sequencing [1, 41]. RWE analysis can better represent the clinical effectiveness of a medicine in local clinical practice [40]Requires substantial support from all stakeholders. Data infrastructure allowing for subsequent HTA reviews does not necessarily mean less labour [1, 40]. Taiwan abandoned this framework in 2020 because agreement could not be reached with the sponsor and the RWE analysis indicated that some indications compared unfavourably with existing treatments [41]Re-assessment and price reduction when new indications have a likely substantial budget impactIn Belgium, a single price for all indications is adopted [3, 28]. For new indications which are not cost-effective at the current price but do not have a substantial budget impact (< 2.5 million euros per year), price reductions are not required [28]. For new indications which do have a substantial budget impact, price reductions are required using a formula which takes into account the cost-effective price and volumes of use of each indication [28]Reduces the additional expenditure associated with new indications [3]Requires complex and time-consuming negotiations between the payer and sponsor [3]. Final price of the medicine is highly sensitive to launch sequencing [3]Indication-specific RSAsItaly implemented indication-specific RSAs for bevacizumab across seven indications. The RSAs share risk through cost sharing, pay-by-results and annual capping [36, 38, 42]Addresses the health and economic impacts of each indication [38]Requires extensive data infrastructure, such as registries, to monitor the medicine’s health impact [36, 38]. This does not replace the assessment process and hence may not reduce delays in patient access [42]Pricing frameworksDifferent price for each indicationDifferent prices can be applied as different brand names or when indications cross distinct therapeutic areas [3, 6, 25, 45, 47–49, 51, 52]Clearly aligns price with the value of each indication, arguably maximising both population health and sponsor profit [45, 47]. Encourages the launch of new indications irrespective of clinical benefit, broadening treatment options [3]Requires substantial utilisation-data infrastructure. May face legal barriers and a risk of arbitrage [3, 25, 45, 47, 51, 65]Different discount for each indicationAll indications have the same public price, but discounts, premiums or clawbacks are applied to reflect the value of each indication [3, 6, 25, 45]Captures the value of each indication, especially when value and utilisation are reasonably certain [3, 6]Requires substantial utilisation-data infrastructure. Public price does not align with value. Revenue for the sponsor and budget impact for the payer may be uncertain [3, 25, 38, 46, 51, 61, 65]Weighted average priceIndications are priced separately as per their value. Then the average price of all indications is calculated, with indications being weighted by expected or actual patient numbers and/or volumes of use [3, 25, 38, 45, 59, 60, 62, 65]Takes into account the value of each indication, which can help maximise access and population health and does not require infrastructure to monitor indications for the risk of arbitrage [3, 25, 46, 51]The price does not directly correspond to each indication’s value, which makes HTA difficult when the medicine is used as a comparator [45]. Does not consider budget implications [53]. Requires monitoring infrastructure if re-calculation of the weighted average price is needed [3, 6, 51]Volume-based discountsAs new indications are launched, discounts are applied across all indications to account for increased usage and economies of scale [3, 6, 45, 46, 48, 54, 63]Italy is moving away from IBP in favour of this simpler framework [6]Does not properly reward R&D efforts and the value of each indication. May disincentivise sponsors from launching new indications [3, 45, 46, 48]. May require complex price negotiations [46]Uniform price for all indicationsA single price (usually the price of the first-launched indication) is maintained for subsequent indications [3, 45, 46, 48, 57, 58]This would, theoretically, result in a lower price for subsequent indications which may have otherwise been valued higher (through IBP) [58]Serious risk of launch sequencing and the price of the medicine is not linked to its value for each indication, which may result in no reimbursement for some indications [49, 58]HTA health technology assessment, MYMI muti-year multi-indication, IBP indication-based pricing RSA, risk-sharing arrangement; R&D, research and development; RWE, real-world evidence Policy and pricing frameworks for multi-indication medicines HTA health technology assessment, MYMI muti-year multi-indication, IBP indication-based pricing RSA, risk-sharing arrangement; R&D, research and development; RWE, real-world evidence Three dedicated policy frameworks for multi-indication medicines were discussed in 11 documents [1, 3, 28, 36–43]. Only two HTA agencies (Belgium and the Netherlands) reported specialised pathways for multi-indication medicines on their websites [28, 39]. Table 3 provides more detail on the nature of these frameworks. Pricing frameworks were more common, being discussed in 27 documents [3, 6, 25, 38, 42–64]. Most of these frameworks discussed indication-based pricing (IBP) [25, 38, 43, 57–59, 61, 65]. IBP refers to the general idea that, because the expected incremental health benefits of a medicine may differ greatly across indications, the individual or social willingness to pay for those medicines may likewise differ across indications [25, 45]. Hence, different indications should be associated with different prices [25, 43, 45, 65]. However, in practice, this may not occur and depends on how IBP is operationalised. The literature reported three ways to operationalise IBP: using a different price for each indication, using a different discount for each indication or using a single weighted-average price (Table 3) [45]. Researchers noted four main benefits of IBP. First, it prevents price erosion, since indications with lower incremental clinical benefits can be launched without the sponsor risking any lowering of price for another indication. Second, IBP prevents launch sequencing (where pharmaceutical companies strategically launch certain indications so the medicine is valued at a higher price) [65]. Third, IBP increases alignment between value and price. Finally, IBP increases research and development incentives, since added clinical benefits resulting from innovation are rewarded with higher prices [38, 43, 45, 49, 57, 58, 61, 65]. HTA Evaluation Methods and Decision-Making Frameworks Four HTA evaluation methods for multi-indication medicines were discussed across eight sources [5, 50, 64, 66–70], and three decision-making frameworks were discussed across four sources [36, 47, 50, 67]. These frameworks are presented in Table 4. A more detailed description is provided in Appendix 2 in Supplementary Files. HTA evaluation methods used to assess multi-indication medicines mainly related to the structure of economic models used for these medicines and whether the incremental cost-effectiveness ratios (ICERs) should be reported separately or aggregated across all indications. Different evaluation methods (e.g. a single ICER, weighted ICER, etc.) corresponded to different decision-making frameworks, namely whether the funding decision is stratified (a decision is made for each indication separately), not stratified (a decision is made for all indications together) or partially stratified (a decision is made for only particular indications, selected on theoretical or empirical grounds) [67]. Table 4HTA evaluation methods and associated decision-making frameworks for multi-indication medicinesHTA evaluation methodDecision-making frameworkDescriptionKey factor guiding reimbursement decisionsReported advantagesReported disadvantagesSingle ICER for each indicationFull stratificationAn economic analysis is performed separately for each indication [50, 67]. A reimbursement decision is then made for each indication [36, 47, 50]. This is usually how jurisdictions handle multi-indication medicines [10, 91]Indication-specific ICERProvides funded access to all cost-effective indications [47]No savings due to economies of scale. Difficult to consider budget implications [50]. May not be practical to restrict reimbursement by indication owing to logistical, practical or ethical considerations [47]. May require indication-specific prices [67]Weighted ICERFull stratification or partial stratificationAn economic analysis is performed for each indication, and the weighted average ICER is calculated on the basis of the proportion of patients in each indication per year in the relevant jurisdiction [69]. A reimbursement decision can then be made using the weighted ICER or the ICER for certain indications (re-weighted for those indications or separately), on the basis of theoretical or empirical grounds (such as biological rationale or data) [67]Weighted ICER and indication-specific ICERCan account for changes in the distribution of patients in each indication over time and across jurisdictions. This would also prevent reimbursement for indications that are implausibly effective/cost-effective (as these indications can be excluded) [67]Requires monitoring by indication to prevent non-reimbursed-indication usage (leakage) [67]Pooled ICERNo stratificationIndications are pooled together in the intervention arm, and the comparator arm is weighted to match those. Economic analysis is then performed, producing an ICER for the resulting population mix [64, 67, 69, 70]Pooled ICERMost suitable when patient numbers are small and thus sub-group analyses are not possible [64, 70]Does not account for heterogeneity in clinical effectiveness across indications [67, 69, 70]. The patient mix may differ between the intervention arm and the population of the jurisdiction concerned [69]BIA for all indicationsN/AA budget impact analysis that includes all indications is conducted [1, 66]Budget impact of the medicine in all indicationsNoneNoneBIA budget impact analysis, HTA health technology assessment, ICER incremental cost-effectiveness ratio HTA evaluation methods and associated decision-making frameworks for multi-indication medicines BIA budget impact analysis, HTA health technology assessment, ICER incremental cost-effectiveness ratio There were a range of key purposes associated with multi-indication frameworks identified in the literature. Several papers were seeking an approach to accelerate patient access to medicines [1, 40, 42, 46]. Others were seeking to reduce the workload burden on HTA agencies [1, 3, 6, 42]. Frameworks were developed to facilitate the analysis of real-world data [1, 3, 40, 41] or to address the heterogeneity in clinical effectiveness observed across indications [36, 58, 67, 69–71]. Several frameworks were created to allow IBP principles to be followed [3, 25, 45, 46, 49, 58, 59, 62, 65], while others were concerned with creating indication-specific risk-share arrangements (RSAs) [46, 48, 53]. Some frameworks were committed to ensuring that no new utilisation-data infrastructure would be required [3, 38, 60] or that the public price would reflect the actual price of the medicine [25, 45, 65]. Several frameworks also wanted to ensure that launch sequencing was not incentivised [1, 25, 47, 49, 65]. Finally, a number of the frameworks were developed to ensure that there was no heightened risk of arbitrage (when medicines are purchased for a lower-priced indication but then used in a higher-priced indication) [3, 25, 45, 61, 65]. A comparison of the frameworks in terms of these characteristics is presented in the form of a heat map in Fig. 2. This reflects only those characteristics reported in the extant literature, without additional interpretation by the authors. Comparison of the characteristics of different multi-indication medicine HTA and reimbursement frameworks. HTA health technology assessment, ICER incremental cost-effectiveness ratio, IBP indication-based pricing, RWE real-world evidence Discussion The aim of this scoping review is, first, to identify any existing HTA and reimbursement frameworks for multi-indication medicines and, second, to examine whether any of those frameworks (or elements therein) could be usefully implemented in Australia or countries with similarly well-established HTA systems. We grouped the identified frameworks into four categories: policy frameworks, pricing frameworks, HTA evaluation methods and decision-making frameworks. Documents discussing pricing frameworks were the most prevalent (n = 27), and very few jurisdictions (only Belgium and the Netherlands) reported specific accelerated HTA pathways for multi-indication medicines on their official websites. However, peer-reviewed literature suggests that such pathways have been used more widely, particularly in response to the emergence of programmed death-(ligand) 1 [PD-(L)1] inhibitors [1, 41, 53]. Efficient HTA Pathways and Evaluation Processes for Multi-indication Medicines This review identified several HTA processes that could be applied in Australia and similarly established HTA systems to decrease duplication of effort and delays associated with funding decision-making for multi-indication medicines. Several HTA agencies have considered using these processes, particularly in relation to histology-independent medicines [67, 72]. For example, in Australia, the pharmaceutical industry has suggested multi-year multi-indication (MYMI) agreements and bundled assessments to the PBAC in relation to funding PD-(L)1 inhibitors, with the PBAC concluding that a multi-indication submission may be acceptable if risk-sharing arrangements and price reductions are proposed for advanced and metastatic cancers and there is coverage for rare cancers [72–74]. Despite almost all of the canvassed jurisdictions requesting separate submissions for each of the multiple indications, recently some HTA organisations have accepted single submissions across multiple indications, perhaps owing to the small patient populations within each indication [6, 75–77]. After three submissions and re-submissions, the PBAC accepted a weighted ICER in conjunction with a single ICER analysis for each indication treated by larotrectinib and considered these to be cost-effective [75]. Canada’s Drug Agency acted similarly for the same medicine, accepting single ICERs for each indication [77]. In the UK, the National Institute for Health and Care Excellence (NICE) rejected a pooled ICER analysis for the same medicine owing to being unable to account for the varying degrees of heterogeneity across indications (it was subsequently included in the Cancer Drugs Fund) [76]. These experiences suggest that, if a multi-indication HTA pathway were developed to allow for multiple-indication submissions in Australia and other countries from established HTA systems but without such a process, decision-makers would likely require clinical and economic evaluations to be done on a per-indication basis (but within one submission) and for a weighted ICER to be presented across all indications [69, 75]. This has also been recommended in a NICE report looking into economic evaluations for multi-indication diagnostic technologies [78]. The difficulty with this approach is that there is often insufficient clinical and economic evidence available for all indications at the same time, since multi-indication medicines typically develop evidence for indications consecutively [79]. One approach that could increase the upfront efficiency of HTA pathways, for indications that are launched consecutively, is to conduct a full HTA for the common indications and then adopt streamlined incremental HTAs alongside conditional reimbursement for subsequent indications. These subsequent evaluations could incorporate real-world evidence (RWE) (including pay-for-performance data) or confirmatory trial data when they are due to report. This approach is similar to that undertaken in the Netherlands, Belgium and Taiwan, although in those instances, traditional HTAs were undertaken rather than abbreviated or streamlined assessments [1, 41]. The first row of the heat map (Fig. 2) highlights that this process meets several of the key attributes sought after by the literature in our scoping review. Notably, this was the only framework which was reported to accelerate patient access. Conditional reimbursement is not a new concept in HTA, since many jurisdictions have formal coverage with evidence development (CED) pathways [80]. For example, Managed Access Programs (MAPs) have been used in Australia for many years, usually in exceptional circumstances, such as in disease areas of high unmet clinical need, with the aim of resolving specific uncertainties arising from submissions through the incorporation of updated data [81]. However, for routine conditional reimbursement of a multi-indication medicine, there must be some presumption that the medicine is broadly effective and cost-effective, in most of its indications. This presumption is needed to warrant public funding [82]. The presumption may be reasonable if there is a biological rationale for why a medicine may be clinically effective across multiple indications. For example, PD-(L)1 inhibitors target the same DNA and RNA sequences across different indications [64]. Morona et al. [83] recommended that a biological plausibility analysis be presented when pan-tumour biomarker testing applications are made to Australia’s Medical Services Advisory Committee. Given that cost-effectiveness can be addressed post-decision-making (i.e. through price adjustments of the medicines or through disinvestment), a streamlined HTA could prioritise the clinical evaluation aspects of an HTA to ensure clinical effectiveness prior to conditional reimbursement. We are currently undertaking research to identify those areas of similarity and duplication across HTAs of multi-indication medicines, which could potentially be targeted in streamlined assessments. Subsequent re-evaluation of multi-indication medicines using RWE remains a contentious issue. In HTA, the acceptance of RWE to establish comparative clinical efficacy or effectiveness is low, with many HTA agencies citing issues with data quality and acceptability, bias and confounding, a lack of HTA methods to conduct RWE analysis, concerns regarding trust and transparency, and a lack of standardisation and transferability [31]. The Australian HTA Policy and Methods Review recommended (Recommendations 27-31) that data infrastructure be set up to appropriately collect RWE for the purposes of HTA and that frameworks be developed to standardise RWE collection, analysis and use [18]. The inherent limitation of RWE is the lack of randomisation and thus the introduction of confounders, which create uncertainty in the magnitude or direction of clinical effects when comparing a new intervention against existing treatment. While statistical methods and causal analysis are useful in addressing this limitation, they cannot account for confounders that are not measurable or observable, and would be accounted for by randomisation [31]. Pricing of Multi-indication Medicines This review identified several pricing frameworks for multi-indication medicines, most of which follow the principles of IBP. This concept and its advantages and disadvantages have been discussed extensively by previous IBP systematic reviews which have been included in our scoping review [25, 45]. However, we did not aim to update these reviews as our focus was broader, examining the range of HTA and reimbursement frameworks, beyond pricing alone. Previous reviews argue that IBP allows for better alignment between the value and price of a medicine at the indication level [3, 25, 45, 49, 51]. Australia has implemented IBP for decades, and it appears that the pharmaceutical industry is supportive of this and believes it should be preserved [84]. From the payer’s perspective, multi-indication medicines represent a significant risk to budget sustainability owing to the volumes of sales of one product [1]. Some scholars appear to believe that discounts due to volumes of sales from the same medicine are an important factor to be considered when price negotiations take place [1, 46, 48, 53–55, 66]. Following other jurisdictions (Italy, Belgium and Korea), one option to consider would be the incorporation of specific algorithms for calculating a single price for a multi-indication medicine, taking into account volumes of sales from all indications [28, 48, 66]. Alternatively, an approach that makes the budget impact of a multi-indication medicine more predictable may be preferable. Belgian HTA stakeholders recommend regular re-evaluation of indication-specific utilisation data to ensure that the estimated weighted average price of a medicine is accurate [3]. This practice could be adopted immediately in Australia with the current data infrastructure. PBAC’s Drug Utilisation Sub-committee occasionally does this, not to re-price a medicine but to monitor for leakage outside the listed indication [85]. Another approach would be to adopt a subscription-type arrangement with industry sponsors where a set price is paid per year for a medicine for use in all of its indications (which may vary across years depending on the launch of new indications), comparable to MYMI agreements trialled in Belgium and the Netherlands and to the ‘delinked payment’ approach used in the UK [1, 86, 87]. Australia was considered a pioneer of this model when it negotiated a set price (1.2 billion AUD, 773 million USD) for an unlimited supply of direct-acting antiviral treatments for the treatment of hepatitis C over 5 years (2016–2021) [86, 88]. Despite retrospective reviews finding this approach successful (93,400 additional patients were treated, the prevalence of hepatitis C decreased by 58% and the government saved 7.4 billion AUD, 4.8 billion USD), a similar type of arrangement has not been adopted since [88–90]. Given that, internationally, volume-based agreements have been reported to be simpler to implement, this approach by Australia may also improve HTA efficiency [6, 63]. Pricing frameworks for multi-indication medicines must balance the value of the medicine per indication with the budget impact of the medicine as a whole. They must also be supported by both payer and sponsor. Given this, greater stakeholder consultation is needed to ensure that health systems can continue to provide cost-effective medicines within constrained budgets, especially given that the production of multi-indication medicines is likely to increase, including because of artificial intelligence (AI) use in medicine development. Limitations This article sought to systematically identify all policies, processes, pathways and methods associated with the HTA and reimbursement of multi-indication medicines in well-established HTA systems, internationally. However, a substantial amount of HTA is conducted in jurisdictions that are non-English speaking. While document translations were performed, the authors cannot discount the possibility that some processes for multi-indication medicines presented on non-English websites were missed. Similarly, it is possible that some of the collated guidance documents and accounts of policies, frameworks and processes were out-of-date, with actual practice having moved ahead of the documentation. Finally, some literature reports that price negotiations for medicines occurs confidentially and are not detailed in the public domain. It is therefore uncertain whether additional frameworks or approaches have been adopted but not documented and therefore not captured in this scoping review [1, 38, 65]. Conclusions Several approaches have been proposed for assessing and reimbursing multi-indication medicines. The most promising approach may be to conduct streamlined health technology assessments (HTAs) for subsequent indications, with funding conditional on real-world evidence (RWE) generation and analysis for the subsequent indications. This has proven to accelerate patient access, although the methodological characteristics of such an approach have yet to be defined. Given the large budgetary impact of multi-indication medicines, pricing frameworks are predominantly used in HTA internationally. Pricing frameworks should balance the value of each indication against the medicine’s budget impact across all indications. This can be achieved with some form of indication-based pricing (IBP), or with payers and sponsors agreeing to an alternative payment arrangement, such as subscription-type arrangements or different RSAs. Stakeholder consultation is needed to determine which of the identified approaches are most feasible, including with local modifications. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (DOCX 200 KB) Funding This research received no specific grant from any funding agency, commercial or not-for-profit sector. The University of Adelaide sponsored the open access fee. Declarations Conflict of Interest The authorship team receive funding from the Australian Federal Government to undertake health technology assessments of new medicines submitted for public funding under the Pharmaceutical Benefits Scheme. The Australian Government had no role in the conception or development of this study. Availability of Data and Material Not applicable. Ethical Approval Not applicable. Consent to Participate Not applicable. Consent for Publication Not applicable. Code Availability Not applicable. Author Contributions Concept and design: Luc, Carter, Merlin. Acquisition of data: Luc, Laka. Analysis and interpretation of data: Luc, Laka, Carter, Merlin. Drafting of the article: Luc, Laka. Critical revision of the article for important intellectual content: Luc, Laka, Carter, Merlin. Supervision: Carter, Merlin. All authors read and approved the final version. References Associated Data Supplementary Materials Supplementary file1 (DOCX 200 KB)